# Risk Factors Associated with Cognitive Decline after Cardiac Surgery: A Systematic Review

Authors: Nikil Patel; Jatinder S. Minhas; Emma M. L. Chung
Journal: Cardiovascular Psychiatry and Neurology
 (2015)

---

## Abstract

Modern day cardiac surgery evolved upon the advent of cardiopulmonary bypass machines (CPB) in the 1950s. Following this development, cardiac surgery in recent years has improved significantly. Despite such advances and the introduction of new technologies, neurological sequelae after cardiac surgery still exist. Ischaemic stroke, delirium, and cognitive impairment cause significant morbidity and mortality and unfortunately remain common complications. Postoperative cognitive decline (POCD) is believed to be associated with the presence of new ischaemic lesions originating from emboli entering the cerebral circulation during surgery. Cardiopulmonary bypass was thought to be the reason of POCD, but randomised controlled trials comparing with off-pump surgery show contradictory results. Attention has now turned to the growing evidence that perioperative risk factors, as well as patient-related risk factors, play an important role in early and late POCD. Clearly, identifying the mechanism of POCD is challenging. The purpose of this systematic review is to discuss the literature that has investigated patient and perioperative risk factors to better understand the magnitude of the risk factors associated with POCD after cardiac surgery.


---

## Body

## 1. Introduction

Neurological complication after cardiac surgery is of a considerable concern and debate exists as to which perioperative factors may be responsible for this adverse injury. Significant advances in all aspects of intraoperative and postoperative care mean cardiac surgery is now safer than ever before [1]. However, as the complexity of surgical procedures increases and the population ages, neurological manifestations and adverse cognitive outcomes are of concern. Cognitive decline limits the ability to complete activities of daily living [2] and increase the likelihood of dependence after discharge [3]. It is therefore paramount to determine the aetiology and extent of brain injury. Such complications vary from subtle cognitive impairment to catastrophic stroke events. The complexity of the brain is demonstrated by small lesions potentially causing significant loss of function, with larger lesions on occasion causing asymptomatic outcomes.Over time, the demographic characteristics of patients undergoing cardiac surgery have shifted to include a higher proportion of elderly patients, undergoing increasingly complex procedures. The average age of cardiac surgery patients has increased from ~64 years in 2001 to ~67 years in 2010. The number of patients with neurological disease prior to surgery has nearly doubled from 1.4% in 2001 to ~2.8% in 2010. Cardiac surgery procedures have also become more complex, with the number of patients undergoing isolated coronary artery bypass graft (CABG) decreasing by almost 20% from 2001 to 2010. Despite higher patient risk profiles, the mortality rate has fallen slightly from 4.0% in 2001/2002 to 3.1% in 2010/2011 (National Cardiac Surgery Audit, UCL, 2012).Routine clinical examination covers crucial neurological abnormalities such as ataxia, visual defects, paresis, and hypaesthesia [4]. It also includes focal neuropsychological deficits such as apraxia, dyscalculia, and aphasia. However, more global cerebral dysfunction, such as neuropsychological decline, mood, and memory disturbances, personality changes, and decline in psychomotor speed are commonly missed because they require more explicit examination using specialised neuropsychological tests [5]. Postoperative cognitive decline (POCD) broadly refers to difficulties associated with memory and general information processing after surgery. At present POCD is not documented in the International Classification of Diseases and is not listed as a diagnosis.


## 2. Methods

### 2.1. Data Sources

A systematic literature search was conducted from searching articles from PubMed and EMBASE. Search terms were created by combining the following medical subject headings (MeSH terms): “Coronary Artery Bypass” OR “Coronary Artery Bypass, Off-Pump” OR “Valve Surgery” OR “Thoracic Surgery” OR “Cardiac Surgical Procedures” AND “Cognitive Therapy” OR “Cognition Disorders” OR “Cognition” OR “Neuropsychology” OR “Neuropsychological Tests” OR “Mild Cognitive Impairment.”


### 2.2. Study Selection

All studies published in English between June 1967 and August 2014 and featuring adult human subjects were eligible for review. Abstracts were excluded if they involved paediatric surgery, operations other than cardiac surgery, or no measurement of cognitive function. Case reports and studies of cardiac procedures such as angioplasty, angiography, valvuloplasty, and Transcatheter Aortic Valve Implantation (TAVI) were also excluded. Studies generating multiple publications from the same cohort were reported only once.


### 2.3. Quality Assessment

Abstracts involving both cardiac surgery and cognitive function were independently reviewed by two investigators (Nikil Patel and Emma M. L. Chung) and studies of adult cardiac surgery patients that assessed both before and after operative cognitive function were identified for full paper review. Where there was disagreement among investigators the full text was reviewed. Additionally, the reference lists of selected articles were evaluated for any additional articles of interest.


### 2.4. Analysis

Articles short-listed for full manuscript review were summarised in an Excel spreadsheet listing the study design (observational, RCT, etc.), number of patients, type(s) of surgery, outcome measures, and time point of neurocognitive assessment. Studies that included assessment of anxiety and depression were also recorded, as these conditions can impact the outcome of cognitive assessments. There was insufficient homogeneity between studies to allow a quantitative, meta-analytic approach of region of interest studies. Therefore, a critical, systematic review was undertaken.


## 2.1. Data Sources

A systematic literature search was conducted from searching articles from PubMed and EMBASE. Search terms were created by combining the following medical subject headings (MeSH terms): “Coronary Artery Bypass” OR “Coronary Artery Bypass, Off-Pump” OR “Valve Surgery” OR “Thoracic Surgery” OR “Cardiac Surgical Procedures” AND “Cognitive Therapy” OR “Cognition Disorders” OR “Cognition” OR “Neuropsychology” OR “Neuropsychological Tests” OR “Mild Cognitive Impairment.”


## 2.2. Study Selection

All studies published in English between June 1967 and August 2014 and featuring adult human subjects were eligible for review. Abstracts were excluded if they involved paediatric surgery, operations other than cardiac surgery, or no measurement of cognitive function. Case reports and studies of cardiac procedures such as angioplasty, angiography, valvuloplasty, and Transcatheter Aortic Valve Implantation (TAVI) were also excluded. Studies generating multiple publications from the same cohort were reported only once.


## 2.3. Quality Assessment

Abstracts involving both cardiac surgery and cognitive function were independently reviewed by two investigators (Nikil Patel and Emma M. L. Chung) and studies of adult cardiac surgery patients that assessed both before and after operative cognitive function were identified for full paper review. Where there was disagreement among investigators the full text was reviewed. Additionally, the reference lists of selected articles were evaluated for any additional articles of interest.


## 2.4. Analysis

Articles short-listed for full manuscript review were summarised in an Excel spreadsheet listing the study design (observational, RCT, etc.), number of patients, type(s) of surgery, outcome measures, and time point of neurocognitive assessment. Studies that included assessment of anxiety and depression were also recorded, as these conditions can impact the outcome of cognitive assessments. There was insufficient homogeneity between studies to allow a quantitative, meta-analytic approach of region of interest studies. Therefore, a critical, systematic review was undertaken.


## 3. Results

A total of 638 abstracts were systematically identified using our search criteria of which 426 papers were suitable for full review. Of these, 296 were observational studies and 130 were RCTs. Although over 420 original research articles were identified as having investigated cognitive decline following cardiac surgery, we found little consensus on the incidence, severity, and time course of symptoms. Differing methodologies used between studies made it difficult to directly compare study findings through systematic meta-analysis.


### 3.1. Time of Postoperative Testing and Cognitive Decline

Most studies evaluating cognitive decline focus on changes in executive function, learning language, visual spatial skills, attention, and memory [6]. However, neuropsychological tests vary considerably between studies and also appear to depend on the timing of neurocognitive assessment. By narrowing the search to empirical research articles that studied postoperative neuropsychological assessment as a primary outcome, the number of publications was reduced to 137 articles. Thirty-three of these articles were excluded because the total percentage of patients who declined in cognitive tests was unclear. Four articles had published the same data twice and full-texts were unavailable for 6 articles. A total of 94 studies were identified to establish the distribution of cognitive decline over several time points. Grouping studies where assessments were performed at similar time points and plotting the proportion of patients estimated to be affected by cognitive decline suggest that 40–60% of patients experience cognitive decline when tested within 2 weeks of surgery, falling to 30–40% after 8–10 weeks, recovering to 10–20% at 1 year, with proportion of patients experiencing cognitive decline increasing again at 3–5 years, Figure 1.Figure 1
Studies attempting to quantify neuropsychological decline at various time points. The weighted mean and standard deviation (number of patients and % decline) are plotted by combining data from a total of 15649 patients and 94 studies; discharge (17 studies), 1-2 weeks (16 studies), 1 month (4 studies), 6 weeks (15 studies), 2-3 months (18 studies), 6 months (11 studies), 1 year (8 studies), and 3–5 years (5 studies).Large variations in the estimated incidence of postoperative cognitive decline are observed, even after grouping studies where tests were performed at similar time points, Figure1. Heterogeneity in assessment methods, patient demographics, and study design may be responsible for these variations.


### 3.2. Perioperative Risk Factors and Cognitive Decline

Further, we investigated perioperative risk factors associated with cognitive decline. Potential mechanisms implicated in the pathogenesis of cognitive decline investigated in previous research resulted in a total of 92 articles (see PRISMA chart in Supplementary Material available online athttp://dx.doi.org/10.1155/2015/370612): anaesthesia: 15 studies; blood pressure: 5 studies; cerebral autoregulation: 4 studies; inflammatory responses: 26 studies; neuroprotective agents: 17 studies; hypothermia and rewarming: 19 studies and 6 studies, respectively.


### 3.3. Anaesthesia

Sedative and anaesthetic agents withN-methyl-d-aspartate receptor antagonist and γ-aminobutyric acid mediated properties can temporarily change the neurotransmission of the brain by interacting at a cellular level to achieve deep sedation during surgery [7]. Since it would be unethical to perform cardiac surgery without the use of anaesthetic agents, the impact of anaesthesia on cognition is difficult to study. Fifteen studies have investigated whether choice of anaesthesia impacts neurocognitive outcome after cardiac surgery. Of these, 8 were randomised controlled trials (RCTs), comparing 7 different types of anaesthetic agent. Studies showing an improvement, decline, and no difference in postoperative outcome are summarised in Table 1.Table 1
Studies comparing cognition after cardiac surgery following administration of different types of anaesthetic.
Study
Study design
Number of patients
Type of anaesthesia/drug
Time of assessment
Outcome
Dumas et al., 1999 [37]
RCT
48
Fentanyl and early extubation
8 weeks
Improved cognition
Dowd et al., 2001 [38]
RCT
78
Propofol and lorazepam
6–12 months
Improved cognition
Bottio et al., 2007 [39]
Obsv.
50
Epidural anaes.
6 months
Improved cognition
Delphin et al., 2007 [40]
Obsv.
91
Sevoflurane and isoflurane
2 hours and 1 day
Improved cognition
Kanbak et al., 2007 [41]
RCT
40
Isoflurane, sevoflurane, and desflurane
3 and 6 days
Improved cognition
Hudetz et al., 2009 [42]
Obsv.
78
Ketamine
1 week
Improved cognition
Schoen et al., 2011 [43]
RCT
117
Sevoflurane and propofol
2, 4, and 6 days
Improved cognition
Kanbak et al., 2007 [41]
RCT
40
Sevoflurane and desflurane
3 and 6 days
Decline
Kadoi et al., 2003 [44]
RCT
180
Propofol and fentanyl
6 months
No difference
Silbert et al., 2006 [45]
Obsv.
300
Fentanyl
1 week, 3 months, 1 year
No difference
Kadoi and Goto, 2007 [46]
Obsv.
109
Sevoflurane
6 months
No difference
Lehmann et al., 2007 [47]
RCT
66
Sufentanil and midazolam
Discharge
No difference
Evered et al., 2011 [48]
Obsv.
281
General anaesthetics
1 week and 3 months
No difference
Parra et al., 2011 [49]
Obsv.
48
Sevoflurane
3 months
No difference
Royse et al., 2011 [50]
RCT
180
Desflurane andpropofol
Discharge and 3 months
No difference
Obsv.: observational.This research suggests that choice of anaesthetic has potential to affect cognition, particularly when tests are performed soon after surgery. However, in the majority of larger studies, the choice of anaesthetic had no impact on cognitive outcome.


### 3.4. Blood Pressure

A number of studies have investigated the association between low blood pressure during cardiac surgery and cognitive decline. Although normal blood pressure in conscious patients is approximately 120/80mmHg, it is common for the blood pressure to be much lower during surgery. As the brain has a lower metabolic demand during anaesthesia, this is not thought to adversely affect tissue perfusion; however, low blood pressure may impair embolus clearance and affect the efficiency of cerebral autoregulation. A total of 5 studies have used neuropsychological tests to investigate whether mean arterial blood pressure had any impact on postoperative cognitive outcome, Table 2.Table 2
Studies investigating POCD associated with intraoperative blood pressure variation.
Study
Study design
Number of patients
Type of intervention
Time of assessment
Outcome
Gold et al., 1995 [8]
RCT
248
High (80–100 mmHg) versus low (50–60 mmHg) BP
6 months
Decline with lower BP
Siepe et al., 2011 [9]
RCT
92
High (80–90 mmHg) versus low (60–70 mmHg) BP
2 days
Decline with lower BP
Gottesman et al., 2007 [51]
Obsv.
15
Low MAP (50–70 mmHg)
3–5 days and 1 month
Decline with lower BP
Newman et al., 1995 [52]
Obsv.
237
Low MAP (50–60 mmHg)
Discharge
Decline with lower BP
Charlson et al., 2007 [10]
RCT
412
High MAP (57–90 mmHg) versus custom (capped at 90 mmHg)
6 months
No difference in outcome
Obsv.: observational.In the study by Gold et al., a higher mean arterial pressure (80–110mmHg) during CPB appeared to be associated with a lower stroke rate (2.4%) compared to a low mean arterial pressure between 45 and 60mmHg (7.2%), p
=
0.026. However, at 6-month follow-up the proportion of patients with neuropsychological declines (11% and 12%, resp.) were comparable [8]. In another study, Siepe et al. showed greater proportion of patients with cognitive decline two days following CABG in patients with mean arterial pressure in the range 60–70mmHg compared to 80–90mmHg; however cerebral oxygen saturation was similar in both groups [9]. The largest RCT by Charlson et al. found no difference in cognition between a “custom” group (average BP: 79mmHg) and High BP group (average BP: 89mmHg); however, the average difference in BP between groups was only 10mmHg, which may not be a clinically significant difference [10]. Overall, studies appear to support the idea that maintenance of a sufficiently high mean arterial pressure during cardiac surgery is important for safeguarding perfusion to the brain.


### 3.5. Cerebral Autoregulation

Some researchers have proposed that it is not mean arterial pressure (MAP)per se that contributes to cognitive decline, but the capacity of the brain’s blood flow regulation mechanisms to respond appropriately to blood pressure variations and changes in oxygen saturation. A number of studies have investigated cerebral autoregulation (CA) in response to blood pressure changes during cardiac surgery and found that a significant proportion of patients struggle to autoregulate their cerebral blood supplies intraoperatively [11]. However, only 4 studies have specifically investigated CA during cardiac surgery in conjunction with pre- and postoperative neuropsychological assessment, Table 3.Table 3
Studies investigating cerebral autoregulation during cardiac surgery in conjunction with neurocognitive tests.
Study
Study design
Number of patients
Cerebral autoregulation  measures
Time of assessment
Outcome
Patel et al., 1993 [53]
RCT
70
Xenon-133 isotope clearance, CMRO2 (cerebral metabolic rate for oxygen), CERO2 (cerebral extraction ratio for oxygen)
6 weeks
Decline with impaired CA
Patel et al., 1996 [54]
RCT
70
CBF, CBFv, and O2 saturation were measured during 4 phases of surgery
6 weeks
Decline with impaired CA
Govier et al., 1984 [55]
Obsv.
67
Partial pressure of arterial carbon dioxide (PaCO2), clearance of xenon-133
Discharge
No difference
Newman et al., 1994 [12]
Obsv.
215
Xenon-133 clearance, CMRO2, cerebral AV difference (C[AV]O2)
Discharge
No difference
Obsv.: observational.All four studies determined pressure-flow and metabolic-flow cerebral autoregulation during cardiopulmonary bypass using the133Xe clearance cerebral blood flow method. Two studies in Table 3 by the same author (Patel et al.) support the theory that impaired cerebral autoregulation is associated with a decline in postoperative outcome at 6 weeks, whereas two studies showed no association. The largest study by Newman et al. investigated CA in 215 patients and concluded that neuropsychological dysfunction at discharge was not explained by impaired CA; however increased oxygen extraction (measured using a thermodilution pulmonary artery catheter) was observed to be associated with a decline in some cognitive tests. They interpreted this suggesting that an imbalance in cerebral tissue oxygen supply may contribute to POCD [12]. In a recent trial it has also been proposed that some anaesthetic agents suppress autoregulatory responses more than others [13]. As far as we are aware, no studies have yet looked at the relationship between CA and POCD beyond 6 weeks.


### 3.6. Inflammatory Responses

All types of surgery have the risk of developing systemic inflammation; however, in cardiac surgery using CPB the blood is exposed to foreign surfaces which have potential to stimulate proinflammatory responses. Inflammation causes endothelial dysfunction, which can lead to leakage between the blood-brain barrier and tissue oedema [14]. It has been shown that cytokines (e.g., TNF-alpha, interleukin-1, and interleukin-6) have been linked to neuropathology [15, 16]. These elementary changes are hypothesised to affect the brain regardless of microembolic load received during surgery [17, 18] and potentially provide an explanation for early cognitive decline [19].Cardiopulmonary bypass components that come into contact with the blood can be coated with biocompatible materials such as poly-2-methoxyethylacrylate, heparin, trillium, and synthetic proteins. These coatings aim to reduce inflammatory responses triggered during CPB. Heparin-coated circuits, in particular, have undergone considerable investigation in previous research. A total of 26 studies (including 7 RCTs) have used neuropsychological tests to investigate whether there is a strong association between inflammation and cognitive decline, Table4.Table 4
Studies investigating whether biomarkers associated with inflammation and/or interventions aimed at reducing inflammation are associated with changes in cognition after surgery.
Study
Studydesign
Number of patients
Marker for cerebral damage
Time of assessment
Outcome
Fitch et al., 1999 [20]
RCT
35
Inhibition of complement activation by specific antibody and no antibody
Discharge
Improved cognition
Heyer et al., 2002 [21]
RCT
99
Inhibition of complement activation by heparin-coated CPB
5 days and 6 weeks
Improved cognition
Baufreton et al., 2005 [19]
RCT
30
Inhibition of complement activation by heparin-coated CPB
Discharge
Improved cognition
Skrabal et al., 2006 [22]
RCT
39
PMEA-coated circuits and noncoated circuits
7–10 days
Improved cognition
Wimmer-Greinecker et al., 1998 [56]
Obsv.
76
>S-100 and NSE
5 days and 2 months
Decline
Jönsson et al., 1999 [57]
Obsv.
132
>S-100
2 weeks and 2 months
Decline
Kilminster et al., 1999 [58]
Obsv.
130
>S-100
6–8 weeks
Decline
Rasmussen et al., 1999 [59]
Obsv.
35
>NSE
Discharge and 3 months
Decline
Derkach et al., 2000 [60]
RCT
27
>S-100 and NSE (deep and mild hypothermic)
6 months
Decline
Diegeler et al., 2000 [61]
RCT
40
>S-100 (on- and off-pump)
1 week
Decline
Georgiadis et al., 2000 [62]
Obsv.
190
>S-100
Discharge
Decline
Lloyd et al., 2000 [63]
RCT
125
>S-100 (on- and off-pump)
3 months
Decline
Basile et al., 2001 [64]
Obsv.
16
>S-100 and NSE
6 months
Decline
Rasmussen et al., 2002 [65]
Obsv.
15
>NSE
Discharge and 3 months
Decline
Farsak et al., 2003 [66]
Obsv.
50
>S-100
Discharge
Decline
Mathew et al., 2003 [67]
Obsv.
460
Reduced preoperative endotoxin immunity
6 weeks
Decline
Jönsson et al., 2004 [68]
Obsv.
56
>S-100
6 months
Decline
Kofke et al., 2004 [69]
Obsv.
28
Apo epsilon 4 allele, >S-100
8 and 24 hrs
Decline
Snyder-Ramos et al., 2004 [70]
Obsv.
64
>S-100 and NSE
Throughout 7 days
Decline
Kálmán et al., 2006 [71]
Obsv.
14
>Cytokine interleukin-6
1 week and 6 months
Decline
Ramlawi et al., 2006 [72]
Obsv.
42
>C-reactive protein
6 hours and 4 days
Decline
Lazibat et al., 2012 [24]
Obsv.
62
>S-100
2 days
Decline
Bayram et al., 2013 [25]
Obsv.
64
>S-100
1 week
Decline
Westaby et al., 2001 [26]
Obsv.
1001
>S-100 and NSE
5 days and 3 months
No difference
Mathew et al., 2005 [73]
Obsv.
440
Statin treatment
6 weeks
No difference
Plaschke et al., 2013 [74]
Obsv.
151
Preoperative serum anticholinergic activity
3 months
No difference
NSE: neuron-specific enolase, PMEA: poly-2-methoxyethylacrylate, and Obsv.: observational.All studies that have randomised patients to receive a heparin-coated CPB system found neuropsychological outcome was better in patients receiving the heparin-coated circuit [19–22]. In studies investigating inflammatory responses, a consensus panel has concluded that “the use of surface-modified circuits might be effective at attenuating the systemic inflammatory response to CPB and improving outcome” [23]. Many markers associated with susceptibility to brain ischaemia such asS-100 beta and neuron-specific enolase (NSE) have been suggested to be associated with an increased risk of cognitive decline [24–26]. Inflammation may also play an important role in our understanding of long-term cognitive function. Biomarkers for inflammation tend to be higher in patients with chronic cardiovascular disease [25]. Overall, the role of inflammation in the pathogenesis of cognitive decline appears to warrant further investigation [27].


### 3.7. Neuroprotective Agents

A number of neuroprotective agents have been investigated to assess whether these could be administered to help preserve neurocognitive function. The results of 17 studies investigating whether neuroprotective agents reduce the incidence of POCD are summarised in Table5.Table 5
RCTs investigating the efficacy of neuroprotection, or neuroprotective agents, in reducing cognitive decline after cardiac surgery.
Study
Number of patients
Type of neuroprotective drug
Time of assessment
Outcome
Grieco et al., 1996 [75]
29
GM-100 (ganglioside) or placebo
1 week and 6 months
Improved cognition
Arrowsmith et al., 1998 [76]
171
Remacemide or placebo
2 months
Improved cognition
Svensson et al., 2002 [77]
403
Mannitol, thiopental, MgSO4, lidocaine
2-3 weeks
Improved cognition
Wang et al., 2002 [29]
118
Lidocaine or placebo
9 days
Improved cognition
Uebelhack et al., 2003 [78]
64
Piracetam or placebo
3 days
Improved cognition
Szalma et al., 2006 [79]
98
Piracetam or placebo
6 weeks
Improved cognition
Haljan et al., 2009 [80]
32
Erythropoietin or placebo
Discharge and 2 months
Improved cognition
Hudetz et al., 2009 [42]
52
Ketamine or placebo
1 week
Improved cognition
Zhang et al., 2011 [81]
200
Benzyl alcohols or saline (placebo)
Discharge and 3 months
Improved cognition
Kong et al., 2002 [82]
245
Chlormethiazole/administration or placebo
4–7 weeks
No difference
Taggart et al., 2003 [83]
150
Imidazoles: low dose (10 mg) or high dose (100 mg) or placebo
5 days and 3 months
No difference
Mathew et al., 2004 [84]
914
Pexelizumab bolus, bolus plus infusion, or placebo
4 days and  1 month
No difference
Mathew et al., 2005 [73]
440
Hydroxymethylglutaryl-CoA reductase inhibitors
6 weeks
No difference
Hogue et al., 2007 [85]
174
17-beta estradiol or placebo
4–6 weeks
No difference
Mathew et al., 2009 [31]
241
Lidocaine or placebo
6 weeks and 1 year
No difference
Mitchell et al., 2009 [32]
158
Lidocaine or placebo
10 weeks and 25 weeks
No difference
Holinski et al., 2011 [86]
88
Piracetam or placebo
3 days
No differenceOne of the most commonly used neuroprotective agents is Lidocaine, which featured in 4 of the 17 studies. Lidocaine is thought to inhibit inflammatory responses during cardiac surgery by modulation of inflammatory mediators, reduction in cerebral metabolism, and deceleration of ischaemic ion fluxes [28]. Two studies showed improved outcome with the use of the drug [29, 30], while two studies showed no difference [31, 32]. Currently, no trials have demonstrated a reproducible clinically significant benefit conferred by the use of any particular neuroprotective drug.


### 3.8. Hypothermia and Rewarming

The patient’s temperature during cardiac surgery has long been thought to play a role in neurological outcome. Several studies have focused their trials on whether reducing the metabolic demand of the brain through hypothermia is neuroprotective. Based on our literature search, 41 studies investigating the effects of temperature were identified. Seventeen studies were excluded from the final result due to lack of clarity in neuropsychological assessments and outcomes. Results from a total of 19 studies investigating the effect of temperature on pre- and postoperative neuropsychological tests are summarised in Table6.Table 6
Studies investigating POCD associated with temperature during cardiac surgery.
Study
Studydesign
Number of patients
Mean temperature (Celsius)
Time of assessment
Outcome
Grimm et al., 2000 [87]
RCT
144
(1) Normothermia: 37°C(2) Hypothermia: 32°C
1 week and 4 months
Improved cognition(with normothermia)
Shaaban-Ali et al., 2002 [88]
RCT
60
(1) Normothermia: 34°C(2) Hypothermia: 28°C
5 days
Improved cognition (with normothermia)
Nathan et al., 1995 [89]
Obsv.
30
Maintain ≤ 34°C
1 week
Improved cognition (with hypothermia)
Grocott et al., 2002 [90]
Obsv.
300
Post-op hypothermia only
6 weeks
Improved cognition(with hypothermia)
Kadoi et al., 2004 [91]
RCT
60
(1) Normothermia: 37°C(2) Hypothermia: 32°C
1 month
Improved cognition(with hypothermia)
Boodhwani et al., 2006 [92]
RCT
448
(1) Normothermia: 37°C(2) Hypothermia: 34°C
1 week
Improved cognition(with hypothermia)
Hiraoka et al., 2012 [93]
Obsv.
11
Hypothermia: 20–22°C
3 weeks and 6 months
Improved cognition(with hypothermia)
McLean et al., 1994 [94]
RCT
155
(1) Hyperthermia: >34°C(2) Hypothermia: <28°C
5 days and 3 months
No difference
Regragui et al., 1996 [95]
RCT
97
(1) Normothermia: 37°C(2) Hypothermia: 28°C & 32°C
6 weeks
No difference
Heyer et al., 1997 [96]
RCT
99
(1) Normothermia: 34°C(2) Hypothermia: 28°C
Discharge and 6 weeks
No difference
Kneebone et al., 1998 [97]
Obsv.
50
(1) Normothermia: 37°C(2) Hypothermia: 30–32°C
1 week
No difference
Reich et al., 1999 [98]
Obsv.
149
(1) Deep hypothermia: 12–15°C (<25 mins)(2) Deep hypothermia: 12–15°C (>25 mins)
1 month
No difference
Kaukinen et al., 2000 [99]
RCT
36
(1) Normothermia: 36-37°C(2) Hypothermia: 28°C
5 days and 11–23 months
No difference
Górna et al., 2001 [100]
Obsv.
33
No full text
3–10 days
No difference
Grigore et al., 2001 [101]
RCT
300
(1) Normothermia: 35.5–36.5°C(2) Hypothermia: 28–30°C
6 weeks
No difference
Kaukuntla et al., 2004 [102]
Obsv.
60
(1) Normothermia: 35°C(2) Differential temperature management
1 and 8 weeks
No difference
Reich et al., 2004 [103]
Obsv.
61
Monitoring during deep hypothermic arrest (28°C)
Discharge
No difference
Boodhwani et al., 2007 [33]
RCT
268
(1) Normothermia: 37°C(2) Hypothermia: 34°C
Discharge and 3 months
No difference
Kunihara et al., 2007 [104]
Obsv.
26
(1) Normothermia: 34°C(2) Hypothermia: 22°C
1 week
No difference
Obsv.: observational.Some studies suggest that hypothermia is more effective than normothermia in protecting the brain during surgery; however, other studies report no obvious difference between “mild hypothermia” and “normothermia” in terms of neuropsychological performance at discharge (49% and 45%, resp.) and at 3 months (4% and 8%, resp.) [33].Some researchers have proposed that the brain could be susceptible to insult during rewarming from hypothermia, particularly if cerebral autoregulation mechanisms are unable to compensate for a sudden increase in metabolic activity associated with changes in temperature. Six studies have been conducted to examine the effect of rewarming rate on POCD, and all of these have shown a benefit in postoperative outcome associated with slower rewarming, Table7.Table 7
Studies investigating POCD associated with the rate of rewarming during cardiac surgery.
Study
Studydesign
Number ofpatients
Mean temperature (Celsius)
Time of assessment
Outcome
Mora et al., 1996 [105]
RCT
138
(1) Rewarm 1-2°C (per increase)(2) Rewarm 3–5°C (per increase)
1–3 days, 7–10 days, and 1 month
Improved cognition with slower rewarm
Nathan et al., 2001 [106]
Obsv.
294
(1) Rewarm to 34°C (1°C per increase)(2) Rewarm to 37°C (3°C per increase)
1 week and 3 months
Improved cognition with slower rewarm
Grigore et al., 2002 [107]
Obsv.
100
(1) Rewarm to 32°C (max within 3 mins)(2) Rewarm to 37°C (max within 3 mins)
6 weeks
Improved cognition with slower rewarm
Kawahara et al., 2003 [108]
RCT
100
(1) Rewarm 1-2°C (per increase)(2) Rewarm 4-5°C (per increase)
1 month
Improved cognition with slower rewarm
Nathan et al., 2007 [109]
RCT
223
(1) Rewarm to 34°C (1°C per increase)(2) Rewarm to 37°C (3°C per increase)
1 week
Improved cognition with slower rewarm
Sahu et al., 2009 [110]
RCT
80
(1) Rewarm 1–3°C (per increase)(2) Rewarm 3–5°C (per increase)
5 days
Improved cognition with slower rewarm
Obsv.: observational.


## 3.1. Time of Postoperative Testing and Cognitive Decline

Most studies evaluating cognitive decline focus on changes in executive function, learning language, visual spatial skills, attention, and memory [6]. However, neuropsychological tests vary considerably between studies and also appear to depend on the timing of neurocognitive assessment. By narrowing the search to empirical research articles that studied postoperative neuropsychological assessment as a primary outcome, the number of publications was reduced to 137 articles. Thirty-three of these articles were excluded because the total percentage of patients who declined in cognitive tests was unclear. Four articles had published the same data twice and full-texts were unavailable for 6 articles. A total of 94 studies were identified to establish the distribution of cognitive decline over several time points. Grouping studies where assessments were performed at similar time points and plotting the proportion of patients estimated to be affected by cognitive decline suggest that 40–60% of patients experience cognitive decline when tested within 2 weeks of surgery, falling to 30–40% after 8–10 weeks, recovering to 10–20% at 1 year, with proportion of patients experiencing cognitive decline increasing again at 3–5 years, Figure 1.Figure 1
Studies attempting to quantify neuropsychological decline at various time points. The weighted mean and standard deviation (number of patients and % decline) are plotted by combining data from a total of 15649 patients and 94 studies; discharge (17 studies), 1-2 weeks (16 studies), 1 month (4 studies), 6 weeks (15 studies), 2-3 months (18 studies), 6 months (11 studies), 1 year (8 studies), and 3–5 years (5 studies).Large variations in the estimated incidence of postoperative cognitive decline are observed, even after grouping studies where tests were performed at similar time points, Figure1. Heterogeneity in assessment methods, patient demographics, and study design may be responsible for these variations.


## 3.2. Perioperative Risk Factors and Cognitive Decline

Further, we investigated perioperative risk factors associated with cognitive decline. Potential mechanisms implicated in the pathogenesis of cognitive decline investigated in previous research resulted in a total of 92 articles (see PRISMA chart in Supplementary Material available online athttp://dx.doi.org/10.1155/2015/370612): anaesthesia: 15 studies; blood pressure: 5 studies; cerebral autoregulation: 4 studies; inflammatory responses: 26 studies; neuroprotective agents: 17 studies; hypothermia and rewarming: 19 studies and 6 studies, respectively.


## 3.3. Anaesthesia

Sedative and anaesthetic agents withN-methyl-d-aspartate receptor antagonist and γ-aminobutyric acid mediated properties can temporarily change the neurotransmission of the brain by interacting at a cellular level to achieve deep sedation during surgery [7]. Since it would be unethical to perform cardiac surgery without the use of anaesthetic agents, the impact of anaesthesia on cognition is difficult to study. Fifteen studies have investigated whether choice of anaesthesia impacts neurocognitive outcome after cardiac surgery. Of these, 8 were randomised controlled trials (RCTs), comparing 7 different types of anaesthetic agent. Studies showing an improvement, decline, and no difference in postoperative outcome are summarised in Table 1.Table 1
Studies comparing cognition after cardiac surgery following administration of different types of anaesthetic.
Study
Study design
Number of patients
Type of anaesthesia/drug
Time of assessment
Outcome
Dumas et al., 1999 [37]
RCT
48
Fentanyl and early extubation
8 weeks
Improved cognition
Dowd et al., 2001 [38]
RCT
78
Propofol and lorazepam
6–12 months
Improved cognition
Bottio et al., 2007 [39]
Obsv.
50
Epidural anaes.
6 months
Improved cognition
Delphin et al., 2007 [40]
Obsv.
91
Sevoflurane and isoflurane
2 hours and 1 day
Improved cognition
Kanbak et al., 2007 [41]
RCT
40
Isoflurane, sevoflurane, and desflurane
3 and 6 days
Improved cognition
Hudetz et al., 2009 [42]
Obsv.
78
Ketamine
1 week
Improved cognition
Schoen et al., 2011 [43]
RCT
117
Sevoflurane and propofol
2, 4, and 6 days
Improved cognition
Kanbak et al., 2007 [41]
RCT
40
Sevoflurane and desflurane
3 and 6 days
Decline
Kadoi et al., 2003 [44]
RCT
180
Propofol and fentanyl
6 months
No difference
Silbert et al., 2006 [45]
Obsv.
300
Fentanyl
1 week, 3 months, 1 year
No difference
Kadoi and Goto, 2007 [46]
Obsv.
109
Sevoflurane
6 months
No difference
Lehmann et al., 2007 [47]
RCT
66
Sufentanil and midazolam
Discharge
No difference
Evered et al., 2011 [48]
Obsv.
281
General anaesthetics
1 week and 3 months
No difference
Parra et al., 2011 [49]
Obsv.
48
Sevoflurane
3 months
No difference
Royse et al., 2011 [50]
RCT
180
Desflurane andpropofol
Discharge and 3 months
No difference
Obsv.: observational.This research suggests that choice of anaesthetic has potential to affect cognition, particularly when tests are performed soon after surgery. However, in the majority of larger studies, the choice of anaesthetic had no impact on cognitive outcome.


## 3.4. Blood Pressure

A number of studies have investigated the association between low blood pressure during cardiac surgery and cognitive decline. Although normal blood pressure in conscious patients is approximately 120/80mmHg, it is common for the blood pressure to be much lower during surgery. As the brain has a lower metabolic demand during anaesthesia, this is not thought to adversely affect tissue perfusion; however, low blood pressure may impair embolus clearance and affect the efficiency of cerebral autoregulation. A total of 5 studies have used neuropsychological tests to investigate whether mean arterial blood pressure had any impact on postoperative cognitive outcome, Table 2.Table 2
Studies investigating POCD associated with intraoperative blood pressure variation.
Study
Study design
Number of patients
Type of intervention
Time of assessment
Outcome
Gold et al., 1995 [8]
RCT
248
High (80–100 mmHg) versus low (50–60 mmHg) BP
6 months
Decline with lower BP
Siepe et al., 2011 [9]
RCT
92
High (80–90 mmHg) versus low (60–70 mmHg) BP
2 days
Decline with lower BP
Gottesman et al., 2007 [51]
Obsv.
15
Low MAP (50–70 mmHg)
3–5 days and 1 month
Decline with lower BP
Newman et al., 1995 [52]
Obsv.
237
Low MAP (50–60 mmHg)
Discharge
Decline with lower BP
Charlson et al., 2007 [10]
RCT
412
High MAP (57–90 mmHg) versus custom (capped at 90 mmHg)
6 months
No difference in outcome
Obsv.: observational.In the study by Gold et al., a higher mean arterial pressure (80–110mmHg) during CPB appeared to be associated with a lower stroke rate (2.4%) compared to a low mean arterial pressure between 45 and 60mmHg (7.2%), p
=
0.026. However, at 6-month follow-up the proportion of patients with neuropsychological declines (11% and 12%, resp.) were comparable [8]. In another study, Siepe et al. showed greater proportion of patients with cognitive decline two days following CABG in patients with mean arterial pressure in the range 60–70mmHg compared to 80–90mmHg; however cerebral oxygen saturation was similar in both groups [9]. The largest RCT by Charlson et al. found no difference in cognition between a “custom” group (average BP: 79mmHg) and High BP group (average BP: 89mmHg); however, the average difference in BP between groups was only 10mmHg, which may not be a clinically significant difference [10]. Overall, studies appear to support the idea that maintenance of a sufficiently high mean arterial pressure during cardiac surgery is important for safeguarding perfusion to the brain.


## 3.5. Cerebral Autoregulation

Some researchers have proposed that it is not mean arterial pressure (MAP)per se that contributes to cognitive decline, but the capacity of the brain’s blood flow regulation mechanisms to respond appropriately to blood pressure variations and changes in oxygen saturation. A number of studies have investigated cerebral autoregulation (CA) in response to blood pressure changes during cardiac surgery and found that a significant proportion of patients struggle to autoregulate their cerebral blood supplies intraoperatively [11]. However, only 4 studies have specifically investigated CA during cardiac surgery in conjunction with pre- and postoperative neuropsychological assessment, Table 3.Table 3
Studies investigating cerebral autoregulation during cardiac surgery in conjunction with neurocognitive tests.
Study
Study design
Number of patients
Cerebral autoregulation  measures
Time of assessment
Outcome
Patel et al., 1993 [53]
RCT
70
Xenon-133 isotope clearance, CMRO2 (cerebral metabolic rate for oxygen), CERO2 (cerebral extraction ratio for oxygen)
6 weeks
Decline with impaired CA
Patel et al., 1996 [54]
RCT
70
CBF, CBFv, and O2 saturation were measured during 4 phases of surgery
6 weeks
Decline with impaired CA
Govier et al., 1984 [55]
Obsv.
67
Partial pressure of arterial carbon dioxide (PaCO2), clearance of xenon-133
Discharge
No difference
Newman et al., 1994 [12]
Obsv.
215
Xenon-133 clearance, CMRO2, cerebral AV difference (C[AV]O2)
Discharge
No difference
Obsv.: observational.All four studies determined pressure-flow and metabolic-flow cerebral autoregulation during cardiopulmonary bypass using the133Xe clearance cerebral blood flow method. Two studies in Table 3 by the same author (Patel et al.) support the theory that impaired cerebral autoregulation is associated with a decline in postoperative outcome at 6 weeks, whereas two studies showed no association. The largest study by Newman et al. investigated CA in 215 patients and concluded that neuropsychological dysfunction at discharge was not explained by impaired CA; however increased oxygen extraction (measured using a thermodilution pulmonary artery catheter) was observed to be associated with a decline in some cognitive tests. They interpreted this suggesting that an imbalance in cerebral tissue oxygen supply may contribute to POCD [12]. In a recent trial it has also been proposed that some anaesthetic agents suppress autoregulatory responses more than others [13]. As far as we are aware, no studies have yet looked at the relationship between CA and POCD beyond 6 weeks.


## 3.6. Inflammatory Responses

All types of surgery have the risk of developing systemic inflammation; however, in cardiac surgery using CPB the blood is exposed to foreign surfaces which have potential to stimulate proinflammatory responses. Inflammation causes endothelial dysfunction, which can lead to leakage between the blood-brain barrier and tissue oedema [14]. It has been shown that cytokines (e.g., TNF-alpha, interleukin-1, and interleukin-6) have been linked to neuropathology [15, 16]. These elementary changes are hypothesised to affect the brain regardless of microembolic load received during surgery [17, 18] and potentially provide an explanation for early cognitive decline [19].Cardiopulmonary bypass components that come into contact with the blood can be coated with biocompatible materials such as poly-2-methoxyethylacrylate, heparin, trillium, and synthetic proteins. These coatings aim to reduce inflammatory responses triggered during CPB. Heparin-coated circuits, in particular, have undergone considerable investigation in previous research. A total of 26 studies (including 7 RCTs) have used neuropsychological tests to investigate whether there is a strong association between inflammation and cognitive decline, Table4.Table 4
Studies investigating whether biomarkers associated with inflammation and/or interventions aimed at reducing inflammation are associated with changes in cognition after surgery.
Study
Studydesign
Number of patients
Marker for cerebral damage
Time of assessment
Outcome
Fitch et al., 1999 [20]
RCT
35
Inhibition of complement activation by specific antibody and no antibody
Discharge
Improved cognition
Heyer et al., 2002 [21]
RCT
99
Inhibition of complement activation by heparin-coated CPB
5 days and 6 weeks
Improved cognition
Baufreton et al., 2005 [19]
RCT
30
Inhibition of complement activation by heparin-coated CPB
Discharge
Improved cognition
Skrabal et al., 2006 [22]
RCT
39
PMEA-coated circuits and noncoated circuits
7–10 days
Improved cognition
Wimmer-Greinecker et al., 1998 [56]
Obsv.
76
>S-100 and NSE
5 days and 2 months
Decline
Jönsson et al., 1999 [57]
Obsv.
132
>S-100
2 weeks and 2 months
Decline
Kilminster et al., 1999 [58]
Obsv.
130
>S-100
6–8 weeks
Decline
Rasmussen et al., 1999 [59]
Obsv.
35
>NSE
Discharge and 3 months
Decline
Derkach et al., 2000 [60]
RCT
27
>S-100 and NSE (deep and mild hypothermic)
6 months
Decline
Diegeler et al., 2000 [61]
RCT
40
>S-100 (on- and off-pump)
1 week
Decline
Georgiadis et al., 2000 [62]
Obsv.
190
>S-100
Discharge
Decline
Lloyd et al., 2000 [63]
RCT
125
>S-100 (on- and off-pump)
3 months
Decline
Basile et al., 2001 [64]
Obsv.
16
>S-100 and NSE
6 months
Decline
Rasmussen et al., 2002 [65]
Obsv.
15
>NSE
Discharge and 3 months
Decline
Farsak et al., 2003 [66]
Obsv.
50
>S-100
Discharge
Decline
Mathew et al., 2003 [67]
Obsv.
460
Reduced preoperative endotoxin immunity
6 weeks
Decline
Jönsson et al., 2004 [68]
Obsv.
56
>S-100
6 months
Decline
Kofke et al., 2004 [69]
Obsv.
28
Apo epsilon 4 allele, >S-100
8 and 24 hrs
Decline
Snyder-Ramos et al., 2004 [70]
Obsv.
64
>S-100 and NSE
Throughout 7 days
Decline
Kálmán et al., 2006 [71]
Obsv.
14
>Cytokine interleukin-6
1 week and 6 months
Decline
Ramlawi et al., 2006 [72]
Obsv.
42
>C-reactive protein
6 hours and 4 days
Decline
Lazibat et al., 2012 [24]
Obsv.
62
>S-100
2 days
Decline
Bayram et al., 2013 [25]
Obsv.
64
>S-100
1 week
Decline
Westaby et al., 2001 [26]
Obsv.
1001
>S-100 and NSE
5 days and 3 months
No difference
Mathew et al., 2005 [73]
Obsv.
440
Statin treatment
6 weeks
No difference
Plaschke et al., 2013 [74]
Obsv.
151
Preoperative serum anticholinergic activity
3 months
No difference
NSE: neuron-specific enolase, PMEA: poly-2-methoxyethylacrylate, and Obsv.: observational.All studies that have randomised patients to receive a heparin-coated CPB system found neuropsychological outcome was better in patients receiving the heparin-coated circuit [19–22]. In studies investigating inflammatory responses, a consensus panel has concluded that “the use of surface-modified circuits might be effective at attenuating the systemic inflammatory response to CPB and improving outcome” [23]. Many markers associated with susceptibility to brain ischaemia such asS-100 beta and neuron-specific enolase (NSE) have been suggested to be associated with an increased risk of cognitive decline [24–26]. Inflammation may also play an important role in our understanding of long-term cognitive function. Biomarkers for inflammation tend to be higher in patients with chronic cardiovascular disease [25]. Overall, the role of inflammation in the pathogenesis of cognitive decline appears to warrant further investigation [27].


## 3.7. Neuroprotective Agents

A number of neuroprotective agents have been investigated to assess whether these could be administered to help preserve neurocognitive function. The results of 17 studies investigating whether neuroprotective agents reduce the incidence of POCD are summarised in Table5.Table 5
RCTs investigating the efficacy of neuroprotection, or neuroprotective agents, in reducing cognitive decline after cardiac surgery.
Study
Number of patients
Type of neuroprotective drug
Time of assessment
Outcome
Grieco et al., 1996 [75]
29
GM-100 (ganglioside) or placebo
1 week and 6 months
Improved cognition
Arrowsmith et al., 1998 [76]
171
Remacemide or placebo
2 months
Improved cognition
Svensson et al., 2002 [77]
403
Mannitol, thiopental, MgSO4, lidocaine
2-3 weeks
Improved cognition
Wang et al., 2002 [29]
118
Lidocaine or placebo
9 days
Improved cognition
Uebelhack et al., 2003 [78]
64
Piracetam or placebo
3 days
Improved cognition
Szalma et al., 2006 [79]
98
Piracetam or placebo
6 weeks
Improved cognition
Haljan et al., 2009 [80]
32
Erythropoietin or placebo
Discharge and 2 months
Improved cognition
Hudetz et al., 2009 [42]
52
Ketamine or placebo
1 week
Improved cognition
Zhang et al., 2011 [81]
200
Benzyl alcohols or saline (placebo)
Discharge and 3 months
Improved cognition
Kong et al., 2002 [82]
245
Chlormethiazole/administration or placebo
4–7 weeks
No difference
Taggart et al., 2003 [83]
150
Imidazoles: low dose (10 mg) or high dose (100 mg) or placebo
5 days and 3 months
No difference
Mathew et al., 2004 [84]
914
Pexelizumab bolus, bolus plus infusion, or placebo
4 days and  1 month
No difference
Mathew et al., 2005 [73]
440
Hydroxymethylglutaryl-CoA reductase inhibitors
6 weeks
No difference
Hogue et al., 2007 [85]
174
17-beta estradiol or placebo
4–6 weeks
No difference
Mathew et al., 2009 [31]
241
Lidocaine or placebo
6 weeks and 1 year
No difference
Mitchell et al., 2009 [32]
158
Lidocaine or placebo
10 weeks and 25 weeks
No difference
Holinski et al., 2011 [86]
88
Piracetam or placebo
3 days
No differenceOne of the most commonly used neuroprotective agents is Lidocaine, which featured in 4 of the 17 studies. Lidocaine is thought to inhibit inflammatory responses during cardiac surgery by modulation of inflammatory mediators, reduction in cerebral metabolism, and deceleration of ischaemic ion fluxes [28]. Two studies showed improved outcome with the use of the drug [29, 30], while two studies showed no difference [31, 32]. Currently, no trials have demonstrated a reproducible clinically significant benefit conferred by the use of any particular neuroprotective drug.


## 3.8. Hypothermia and Rewarming

The patient’s temperature during cardiac surgery has long been thought to play a role in neurological outcome. Several studies have focused their trials on whether reducing the metabolic demand of the brain through hypothermia is neuroprotective. Based on our literature search, 41 studies investigating the effects of temperature were identified. Seventeen studies were excluded from the final result due to lack of clarity in neuropsychological assessments and outcomes. Results from a total of 19 studies investigating the effect of temperature on pre- and postoperative neuropsychological tests are summarised in Table6.Table 6
Studies investigating POCD associated with temperature during cardiac surgery.
Study
Studydesign
Number of patients
Mean temperature (Celsius)
Time of assessment
Outcome
Grimm et al., 2000 [87]
RCT
144
(1) Normothermia: 37°C(2) Hypothermia: 32°C
1 week and 4 months
Improved cognition(with normothermia)
Shaaban-Ali et al., 2002 [88]
RCT
60
(1) Normothermia: 34°C(2) Hypothermia: 28°C
5 days
Improved cognition (with normothermia)
Nathan et al., 1995 [89]
Obsv.
30
Maintain ≤ 34°C
1 week
Improved cognition (with hypothermia)
Grocott et al., 2002 [90]
Obsv.
300
Post-op hypothermia only
6 weeks
Improved cognition(with hypothermia)
Kadoi et al., 2004 [91]
RCT
60
(1) Normothermia: 37°C(2) Hypothermia: 32°C
1 month
Improved cognition(with hypothermia)
Boodhwani et al., 2006 [92]
RCT
448
(1) Normothermia: 37°C(2) Hypothermia: 34°C
1 week
Improved cognition(with hypothermia)
Hiraoka et al., 2012 [93]
Obsv.
11
Hypothermia: 20–22°C
3 weeks and 6 months
Improved cognition(with hypothermia)
McLean et al., 1994 [94]
RCT
155
(1) Hyperthermia: >34°C(2) Hypothermia: <28°C
5 days and 3 months
No difference
Regragui et al., 1996 [95]
RCT
97
(1) Normothermia: 37°C(2) Hypothermia: 28°C & 32°C
6 weeks
No difference
Heyer et al., 1997 [96]
RCT
99
(1) Normothermia: 34°C(2) Hypothermia: 28°C
Discharge and 6 weeks
No difference
Kneebone et al., 1998 [97]
Obsv.
50
(1) Normothermia: 37°C(2) Hypothermia: 30–32°C
1 week
No difference
Reich et al., 1999 [98]
Obsv.
149
(1) Deep hypothermia: 12–15°C (<25 mins)(2) Deep hypothermia: 12–15°C (>25 mins)
1 month
No difference
Kaukinen et al., 2000 [99]
RCT
36
(1) Normothermia: 36-37°C(2) Hypothermia: 28°C
5 days and 11–23 months
No difference
Górna et al., 2001 [100]
Obsv.
33
No full text
3–10 days
No difference
Grigore et al., 2001 [101]
RCT
300
(1) Normothermia: 35.5–36.5°C(2) Hypothermia: 28–30°C
6 weeks
No difference
Kaukuntla et al., 2004 [102]
Obsv.
60
(1) Normothermia: 35°C(2) Differential temperature management
1 and 8 weeks
No difference
Reich et al., 2004 [103]
Obsv.
61
Monitoring during deep hypothermic arrest (28°C)
Discharge
No difference
Boodhwani et al., 2007 [33]
RCT
268
(1) Normothermia: 37°C(2) Hypothermia: 34°C
Discharge and 3 months
No difference
Kunihara et al., 2007 [104]
Obsv.
26
(1) Normothermia: 34°C(2) Hypothermia: 22°C
1 week
No difference
Obsv.: observational.Some studies suggest that hypothermia is more effective than normothermia in protecting the brain during surgery; however, other studies report no obvious difference between “mild hypothermia” and “normothermia” in terms of neuropsychological performance at discharge (49% and 45%, resp.) and at 3 months (4% and 8%, resp.) [33].Some researchers have proposed that the brain could be susceptible to insult during rewarming from hypothermia, particularly if cerebral autoregulation mechanisms are unable to compensate for a sudden increase in metabolic activity associated with changes in temperature. Six studies have been conducted to examine the effect of rewarming rate on POCD, and all of these have shown a benefit in postoperative outcome associated with slower rewarming, Table7.Table 7
Studies investigating POCD associated with the rate of rewarming during cardiac surgery.
Study
Studydesign
Number ofpatients
Mean temperature (Celsius)
Time of assessment
Outcome
Mora et al., 1996 [105]
RCT
138
(1) Rewarm 1-2°C (per increase)(2) Rewarm 3–5°C (per increase)
1–3 days, 7–10 days, and 1 month
Improved cognition with slower rewarm
Nathan et al., 2001 [106]
Obsv.
294
(1) Rewarm to 34°C (1°C per increase)(2) Rewarm to 37°C (3°C per increase)
1 week and 3 months
Improved cognition with slower rewarm
Grigore et al., 2002 [107]
Obsv.
100
(1) Rewarm to 32°C (max within 3 mins)(2) Rewarm to 37°C (max within 3 mins)
6 weeks
Improved cognition with slower rewarm
Kawahara et al., 2003 [108]
RCT
100
(1) Rewarm 1-2°C (per increase)(2) Rewarm 4-5°C (per increase)
1 month
Improved cognition with slower rewarm
Nathan et al., 2007 [109]
RCT
223
(1) Rewarm to 34°C (1°C per increase)(2) Rewarm to 37°C (3°C per increase)
1 week
Improved cognition with slower rewarm
Sahu et al., 2009 [110]
RCT
80
(1) Rewarm 1–3°C (per increase)(2) Rewarm 3–5°C (per increase)
5 days
Improved cognition with slower rewarm
Obsv.: observational.


## 4. Conclusion

Neuropsychological function is a soft outcome measure and has proved challenging to quantify postoperatively. Although neuropsychological tests theoretically provide a highly sensitive means of quantifying changes in cognition, differences in test batteries, timing of assessment, and criteria for defining neuropsychological decline generate considerable heterogeneity in the data, which limits our ability to compare the results of different studies. Depending on the timing of the neurocognitive tests and the definition used for determining decline, the reported incidence of neurocognitive decline after cardiac surgery varied extensively. The outcome suggests that 50–70% of patients experience cognitive decline when tested within one week of surgery, falling to 30–50% after 8–10 weeks, recovering to 10–20% at 1 year, and then declines again at 3–5 years. Currently, there is no widely accepted clinical definition of cognitive decline; therefore, it is possible that arbitrary definitions of decline have resulted in an overestimation of the incidence of decline. At present, there is no evidence to suggest that the long-term incidence of cognitive decline differs from that of nonoperative controls. Estimating long-term cognitive decline can be difficult, as normal ageing and dementia interfere with studies with older populations.Further research is required to develop a more dynamic and nuanced picture of interactions between underlying pre- and perioperative risk factors. It is apparent that studies investigating isolated perioperative factors are insufficient to explain complex interactions between temperature, cerebral autoregulation, oxygen saturation, and brain metabolism. To date, isolated interventions and neuroprotective drugs aimed at improving cognitive outcome have proved to be largely ineffective. Literature examining underlying and perioperative risk factors associated with the pathogenesis of cognitive decline suggests that there is no single causative factor responsible for POCD. It seems likely that the causes are multifactorial, due to emboli, impaired perfusion, chronic cardiovascular disease, and inflammatory responses.Interpreting the risk factors associated with postoperative cognitive decline, it seems that efforts to protect the brain during surgery are intrinsically linked with the need to control the progression of cardiovascular disease, especially in older patients. It is possible that patients may be exceeding a “threshold” of preexisting vulnerability where the brain’s ability to compensate for injuries or inflammation during surgery is absent. It is also important to address that cardiac surgery equipment advances are a confounder within this review and should be considered. In summary, the literature examining underlying risk factors and perioperative risk factors associated with the pathogenesis of cognitive decline suggests that there is no single factor responsible for postoperative cognitive decline or single intervention capable of protecting the brain during surgery. Overall, the pathogenesis of cognitive decline following surgery still remains unclear.Several factors have been associated with brain injury including hypoperfusion, arrhythmias, rapid rewarming, and inflammation (local or global) [34–36]. The process of preventing such brain injury involves prevention of such events occurring; however, to date no single intervention has successfully prevented cognitive decline, signalling an increased likelihood of a multifactorial aetiology. The advent of new technologies to prevent physiological stress on the brain has focussed on neuroprotective agents or perfusionist strategies. Although prevention has an important role, it would be ideal to develop methods of protecting or restoring neurocognitive decline to nearer preoperative baselines.Cardiac surgery is a triumph of modern day medicine, and its acceptance as a safe procedure is widespread. Unfortunately, postoperative cognitive issues remain a consideration. As cardiac surgery procedures are now being challenged by less invasive methods, perhaps intraoperative transcranial Doppler monitoring, neuropsychological tests, and neuroimaging will play an increasingly important role in optimising treatment.



---

*Source: 370612-2015-09-30.xml*